ImmunoCellular Therapeutics’ proprietary cancer immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatment than conventional cancer therapies. Our dendritic cell (DC)-based immunotherapies utilize multiple tumor-specific antigens to target cancer stem cells and other tumor cells by triggering a powerful antitumor immune system response. Our proprietary manufacturing process produces multiple doses from a single apheresis and offers the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared with earlier generation cancer immunotherapeutics.

Technology Scientist

Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved